Generic Drug tightens discount on $380 million term loan B to 99½

By Sara Rosenberg

New York, Aug. 13 - Generic Drug Holdings Inc. (Harvard Drug) moved the original issue discount on its $380 million senior secured term loan B (B1/B) to 99½ from 99, according to a market source.

Pricing on the loan is Libor plus 400 basis points with a 1% Libor floor and it includes 101 soft call protection for six months as well as a maximum total leverage ratio.

Earlier in syndication, the spread was reduced from talk of Libor plus 425 bps to 450 bps and the soft call was shortened from one year.

Recommitments were due at 3 p.m. ET on Tuesday, the source added.

Morgan Stanley Senior Funding Inc., Credit Suisse Securities (USA) LLC and Deutsche Bank Securities Inc. are the lead banks on the deal.

Proceeds will be used to refinance existing debt and pay a dividend to shareholders.

Generic Drug is a Livonia, Mich.-based independent pharmaceutical distributor.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.